Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancercell lungsmall cellnsclcheart
  Phrases that lowered it: hormonethe studyfirst administrationadvancedregimen
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 79 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 22.2% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Sponsor's past termination rate: 7.1% (raises risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 416 (raises risk) · Drug's FDA history
• Sponsor's past trials: 156 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 1990 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer NCT00958022 · started 2009 · scored riskier than 95% of active trials terminated
• Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers NCT00738751 · started 2008 · scored riskier than 99% of active trials completed
• Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers NCT01005797 · started 2009 · scored riskier than 66% of active trials completed
• The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC NCT04338399 · started 2020 · scored riskier than 68% of active trials completed
• Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer NCT02167854 · started 2014 · scored riskier than 23% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.